Did Bausch & Lomb and FDA Act Fast Enough?

The New York Times has an article about how the crisis with a Bausch & Lomb contact lens cleaner started in Asia last year but wasn't noticed in North America until much later. Is this going to be another case study of how analysis of adverse event reports needs to get faster and better?

May 18, 2006

1 Min Read
Did Bausch & Lomb and FDA Act Fast Enough?

The New York Times has an article about how the crisis with a Bausch & Lomb contact lens cleaner started in Asia last year but wasn't noticed in North America until much later. Is this going to be another case study of how analysis of adverse event reports needs to get faster and better?

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like